Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study - Biological phase (EPHOS-B)

EPHOS-B is a Phase III, multicentre, three arm, randomised controlled trial in women with HER2+ early breast cancer. The primary objective of the trial is to determine whether pre-operative treatment of HER-2 positive breast cancer patients with anti HER2 therapy inhibits proliferation or increases apoptosis.

These pages at the ICR are for staff involved in the trial. General information about the trial can be found on the Cancer Research UK website.

EPHOS-B Forum

The EPHOS-B forum enables centres to exchange ideas on the day to day running of EPHOS-B in the clinical setting. It allows users to access the latest Newsletters, Updates, and any meeting information - including the Launch meeting (July 2010) slides and audio. 

 Access the EPHOS-B forum (username and password needed)

If you or other staff at your centre would like to register to have access to this forum, please complete the details below and we will send you the log in details by return.

Any queries regarding eligibility, SAEs, the Protocol or Trial Guidance Notes should be emailed directly to the EPHOS-B team